P1500Effects of empagliflozin on cardiac function in patients with type 2 diabetes mellitus: echocardiographic substudy of the EMPA-HEART cardiolink-6 trial

MLA

Geraldine Ong, et al. “P1500Effects of Empagliflozin on Cardiac Function in Patients with Type 2 Diabetes Mellitus: Echocardiographic Substudy of the EMPA-HEART Cardiolink-6 Trial.” European Heart Journal, vol. 40, Oct. 2019. EBSCOhost, https://doi.org/10.1093/eurheartj/ehz748.0263.

APA

Geraldine Ong, David Mazer, M. Zahrani, Kim A. Connelly, Howard Leong-Poi, Vinay Garg, Subodh Verma, S Gandhi, Andrew T. Yan, Edwin C. Ho, K. Bami, Adrian Quan, & Hwee Teoh. (2019). P1500Effects of empagliflozin on cardiac function in patients with type 2 diabetes mellitus: echocardiographic substudy of the EMPA-HEART cardiolink-6 trial. European Heart Journal, 40. https://doi.org/10.1093/eurheartj/ehz748.0263

Chicago

Geraldine Ong, David Mazer, M. Zahrani, Kim A. Connelly, Howard Leong-Poi, Vinay Garg, Subodh Verma, et al. 2019. “P1500Effects of Empagliflozin on Cardiac Function in Patients with Type 2 Diabetes Mellitus: Echocardiographic Substudy of the EMPA-HEART Cardiolink-6 Trial.” European Heart Journal 40 (October). doi:10.1093/eurheartj/ehz748.0263.